CFM
DNLI icon

Cornerstone Financial Management’s Denali Therapeutics DNLI Stock Holding History

Cornerstone Financial Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$874 Hold
34
– – ﹤0.01% 1152
2026
Q1 		$653 Hold
34
– – ﹤0.01% 1078
2025
Q4 		$561 Buy
+34
New +$574 ﹤0.01% 1119

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cornerstone Financial Management's DNLI Position: Q2 2026 in Review

Cornerstone Financial Management held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 34 shares worth $874. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

Cornerstone Financial Management first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Cornerstone Financial Management held 34 shares of Denali Therapeutics worth $874 as of Q2 2026.
  • Cornerstone Financial Management left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #1152 holding.
  • Cornerstone Financial Management first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.